Account

Sign in to access your account and subscription

Who May Sue: Patent Standing Issues and Implications for the Life Sciences Industry (Part II)

In the second part of a two-part article addressing patent standing issues common to companies in the life sciences industry, we examine additional patent standing complications and discuss how mid-litigation transfers of ownership may affect standing, and how standing issues may ultimately impact the availability and scope of damages.

12 minute read April 01, 2026 at 12:11 AM
By
Matthew Chivvis , Sumaiya Sharmeen , Evelyn Li-Jin Chang and Maya Darrow
Who May Sue: Patent Standing Issues and Implications for the Life Sciences Industry (Part II)

Part Two of a Two-Part Article

Introduction



This is the second of a two-part article addressing patent standing issues common to companies in the life sciences industry. In

This premium content is locked for The Intellectual Property Strategist subscribers only

ENJOY UNLIMITED ACCESS TO THE SINGLE SOURCE OF OBJECTIVE LEGAL ANALYSIS, PRACTICAL INSIGHTS, AND NEWS IN The Intellectual Property Strategist

  • Stay current on the latest information, rulings, regulations, and trends
  • Includes practical, must-have information on copyrights, royalties, AI, and more
  • Tap into expert guidance from top entertainment lawyers and experts

Already have an account? Sign In Now

For enterprise-wide or corporate access, please contact Customer Service at [email protected] or call 1-877-256-2473.

NOT FOR REPRINT

© 2026 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Continue Reading

The Copyright Royalty Board (CRB), which works under the umbrella of the Librarian of Congress, sets statutory-license royalty terms and rates. The U.S. Courts of Appeals for the D.C. Circuit recently issued two notable decisions about the CRB.

October 01, 2026